Provider Insights on the Impact of 340B Pricing

TKG PACT Executive Briefings - 3-Minute Market Insights

Innhold levert av The Kinetix Group, Powered by Petauri, The Kinetix Group, and Powered by Petauri. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av The Kinetix Group, Powered by Petauri, The Kinetix Group, and Powered by Petauri eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

26d ago 3:54

MP3•Episoder hjem

Send us a text

Provider Insights on the Impact of 340B Pricing.

We frequently get asked for insights on how the 340B Drug Pricing Program may... or may not... be impacting the prescribing choices of participating covered entities. The Health Resources and Services Administration (HRSA) administers this federal program which is intended to help safety-net providers carry out their missions to serve their communities.

The Kinetix Group (TKG) recently conducted a market access research study to gain insights from healthcare providers on how the 340B program is impacting care delivery in covered entities. You can reach out to us for the full study, but a few of the highlights from our study are included in this briefing

You can download the full Executive Briefing at: https://tkgpact.com/executive-briefings/

Or, feel free to email us at Insights@thekinetixgroup.com

56 episoder

#Fitness #Medicine #The Kinetix Group #Healthcare #Pharma #Voice #Triple Aim #Biotech #Health Management #Science #Alternative Health #Biology #Insight